Mental Health Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Signet Laboratories, Inc.
Availability of polyclonal hepsin antibody announced
December 17th, 2005
Signet Laboratories, Inc., a medical diagnostics/research company specializing in the development of monoclonal antibodies and diagnostic assays for cancer, infectious disease, and neurodegenerative disease, announced the availability of polyclonal hepsin antibody. Hepsin is a cell surface serine protease upregulated in prostate cancer. The functional significance of this upregulation is unknown. Recent studies have reported that hepsin may play a role in the disorganization of the basement membrane and metastasis. Improved screening and early diagnosis have reduced mortality, but the need exists for treatment options and prognostic markers for...
Source: Mental Health Law Weekly (2005-12-17)
|
